Loading patent…
AssigneeHealthPartners Research Foundation
InventorsWilliam H. Frey II, Samuel Scott Panter, Leah Ranae Bresin Hanson
Estimating the term…
Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of cerebral hemorrhage and subarachnoid hemorrhage. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). An effective amount of DFO may be administered to the upper third of the nasal cavity of a patient at risk for, or diagnosed with, cerebral hemorrhage and subarachnoid hemorrhage. The effective amount of DFO is delivered directly to the patient's central nervous system for preconditioning, preventing and/or treating the cerebral hemorrhage and subarachnoid hemorrhage.
1-63. (canceled)
A method to treat a patient with cerebral hemorrhage comprising:
A method to treat a patient with cerebral hemorrhage comprising:
A method to treat a patient with subarachnoid hemorrhage comprising:
A method to treat a patient with subarachnoid hemorrhage comprising:
Dependencies are inferred from the claim text.